-
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-11
A 2026 study identifies dasatinib as a synergistic partner for LRPPRC inhibition in OXPHOS-dependent cancer models. Its central insight is that the two interventions disrupt complementary OXPHOS gene programs: dasatinib preferentially affects nuclear-encoded genes, whereas LRPPRC inhibition impairs mitochondrial genome-encoded transcripts.
-
Cy5-UTP for RNA Probe Synthesis and FISH
2026-09-11
Cy5-UTP streamlines fluorescent RNA probe synthesis for FISH, multiplex imaging, and dual-color expression arrays. This practical guide connects labeling chemistry with STAU2 condensate research while emphasizing assay design, optimization, and troubleshooting.
-
ω-Agatoxin IVA in Epileptogenesis: Study Insights
2026-09-10
This Molecular Neurobiology study shows that selective blockade of P/Q-type Cav2.1 calcium channels with ω-agatoxin IVA suppresses PTZ-associated epileptogenesis in rats while shifting BDNF and cleaved caspase-3 expression toward a pro-survival profile. Its combination of behavioral, freely moving EEG, and regional immunohistochemical analyses provides a useful framework for evaluating Cav2.1 signaling in seizure biology.
-
DRB: Mechanism, Benchmarks, and RNA Polymerase II
2026-09-10
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a CDK-directed transcriptional elongation inhibitor that perturbs RNA polymerase II-dependent RNA synthesis. Its benchmark activities include inhibition of CTD kinases, suppression of hnRNA production in HeLa cells, and inhibition of Tat-enhanced HIV transcription in vitro.
-
Epalrestat Workflows for Polyol Pathway Research
2026-09-09
Epalrestat provides a practical way to interrogate aldose reductase, polyol pathway flux, and redox responses across diabetic neuropathy research, neuroprotection, and exploratory cancer metabolism studies. This guide combines preparation parameters, assay workflows, cross-domain interpretation, and troubleshooting for reproducible oxidative stress research.
-
Baicalin: Pathways, Plasticity, and Cancer Research
2026-09-09
Baicalin is a Scutellaria baicalensis flavone glycoside with reported KEAP1-NRF2/HO-1 pathway modulation and preclinical activity in visual cortical plasticity and cancer research. A 2026 NeuroImage study found that 10 mg/kg baicalin restored ocular dominance plasticity in adult amblyopic mice, while the product dossier reports additional oncology-related pathway applications.
-
How GCG Disrupts SARS-CoV-2 Nucleocapsid Condensation
2026-09-08
The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology. It further shows that the green-tea polyphenol (-)-gallocatechin gallate disrupts this condensation process and suppresses viral replication, providing a framework for studying viral condensates as chemical intervention points.
-
DFCP1, ATGL, and Starvation-Driven Lipolysis
2026-09-07
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism and defines its direct effect on ATGL behavior during starvation. Its key mechanistic insight is that DFCP1 recruits and retains ATGL on lipid droplets, limiting the dynamic lipase exchange required for efficient lipolysis.
-
Gamithromycin: From Ribosome to Translational Strategy
2026-09-07
Gamithromycin, also known as ML-1709460, is more than a macrolide antibiotic catalog entry: its value lies in the connection between 50S ribosomal inhibition, pulmonary exposure, and AUC24h/MIC-driven pharmacodynamics. This thought-leadership article translates the available rabbit pasteurellosis evidence into practical guidance for veterinary infection models, assay design, and translational development.
-
Metformin HCl as a Translational Immunometabolism Tool
2026-09-05
Metformin Hydrochloride is more than a glucose-metabolism reagent. Its linked effects on hepatic gluconeogenesis, AMPK–ACC signaling, lipid handling, and cellular redox create a strategic framework for connecting metabolic perturbation with immune-function assays. This article outlines how translational researchers can validate that bridge without overstating the evidence.
-
Panobinostat-Induced Calcineurin Degradation in Myeloma
2026-09-04
The reference study identifies calcineurin catalytic subunit PPP3CA as a therapeutically relevant target of panobinostat in multiple myeloma. Its experiments connect PPP3CA abundance with advanced disease and bortezomib resistance, while showing that calcineurin-directed combinations can improve antimyeloma activity and suppress osteoclast formation.
-
From Thermal Shifts to Translational Insight
2026-09-04
Translational research increasingly depends on connecting phenotypic activity with direct evidence of ligand engagement. This thought-leadership article shows how thermal shift assay logic, orthogonal validation, and the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) can help researchers move from broad screening to defensible mechanism-of-action hypotheses.
-
Faropenem Sodium: Workflow for PK and AMR Studies
2026-09-04
Faropenem sodium supports integrated antimicrobial, anaerobe, resistance, and renal transport workflows rather than a single endpoint assay. Its PBP-directed activity and Npt1-associated secretion profile allow researchers to connect bacterial inhibition with disposition-oriented experiments.
-
Toremifene Citrate: ER Assay Workflows
2026-09-03
Build more interpretable estrogen receptor experiments with Toremifene Citrate, from receptor-binding benchmarks to breast cancer cell proliferation and translational rodent studies. This workflow emphasizes concentration design, vehicle control, exposure timing, and troubleshooting for reliable hormone receptor modulation.
-
SR 11302: Translating AP-1 Blockade to Oncology
2026-09-02
A translational perspective on SR 11302 as a selective AP-1 transcription factor inhibitor, connecting tumor-cell assays, AP-1-driven chemoprevention, and emerging immune-context studies while defining the evidence needed for rigorous oncology development.